chevron_leftBack
As of 14 June 2026, Northwest Biotherapeutics, Inc. has a market cap of $325.84M USD, ranking #18069 globally and #3008 in the United States.
It ranks #1638 in the Healthcare sector, and #591 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$325.84MUSD
Enterprise Value
$400.33MUSD
Revenue (TTM)
$1.38MUSD
EBITDA (TTM)
-$57.85MUSD
Net Income (TTM)
-$61.48MUSD
PS Ratio
236.5
PB Ratio
-6.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Linda Powers
open_in_new
Employees
105
Founded
1996
Website
nwbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.3% | 2.3% | -3.1% | -32% | -22% | -30% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NWBO
Northwest Biotherapeutics Inc
ISIN: US66737P6007
Shares Out.:
Shares Outstanding:
1.643B1
Shares Float:
1.606B2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.1985 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
234K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
168K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
111K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
84K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
46K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
36K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
99K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
89K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
84K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
56K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
34K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
33K%
80.96B GBP
|
14.6
|
chevron_leftBack